To calculate fair value based on cost of capital and terminal growth assumptions above, please select free cash flow forecast.
Forecast:
Please log in / sign up to calculate fair value based on selected inputs
Valuation
Free Cash Flow Yield
FCF Yield TTM = Trailing Twelve Months free cash flow per share / current market price per shareLearn more
2 %
Dividend Yield TTM
-
Market cap $
$ 52,853
Price / Earnings TTM
P/E TTM = current market price per share / Trailing Twelve Months diluted earnings per shareLearn more
48.8
Price / Book TTM
5.1
PEG TTM
Price/Earnings-to-Growth ratio = P/E TTM divided by most recent annual diluted earnings per share growth rateLearn more
(0.7)
Earnings growth and return
LTM
5YR
10YR
Total return (price & dividends)
17.6 %
(14) %
158.6 %
Free cash flow per share growth
371.1 %
122.6 %
239.8 %
Earnings per share growth
(73.7) %
40.8 %
144 %
Founded: 1,958
Employees: 15,800
Business Summary:Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.
Edwards Lifesciences —
Financial Overview, Stock Price, Market Cap
Edwards Lifesciences is a company. Founded in 1958. As of July 14, 2026, the company's market capitalization is $52852682000 with a current stock price of $91.79.